This month’s hires, promotions, acquisitions and other notable news includes Ajinomoto, Medable, Charles River, Immunai, AstraZeneca and other top firms.
The companies announcing acquisitions, new hires, promotions and other news this month include Syneos, Elligo, PCI Pharma Services, I Holland and more.
Analytical software provider and CRO, Cytel, and biostatistics company, Axio Research, merge to deliver analytical solutions for clinical research drug development challenges.
Boston Biomedical Associates and Factory-CRO Group merge to provide global CRO services with specialized operations worldwide, providing continuity in international clinical research.
The PE firm Ampersand Capital Partners has acquired Pacific Biomarkers and is merging the CRO with Neomed-Labs to streamline clinical immunology development.
Takeda is in talks to sell Shire’s experimental inflammatory bowel disease pipeline in an effort to meet European regulators approval for the acquisition.
Contract research organization (CRO) earnings reports have been filing in over the past few weeks – and as a group, performance was positive following concerns around slowing outsourcing trends.
UDG Healthcare has acquired Cambridge BioMarketing LLC in a deal worth up to $35m as the healthcare service provider looks to continue expansion in the United States.
Genesis Biotechnology Group (GBG) has acquired the preclinical CRO PharmOptima in order to provide customers with a single point-of-contact throughout their drug development programs.
An advisor to the pharma industry on M&A says the current boom in pharma valuations will not last, and R&D cost pressures will reshape firms of the future.
DNA sequencing firm Source BioScience will bolster its stability testing and storage services through a proposed acquisition of Select Pharma Laboratories.
Competition among the top CROs, many of which are conglomerations of smaller peers, is “ferocious” right now on nearly every level, Parexel CEO Josef von Rickenbach told Outsourcing-Pharma.com at the 51st annual DIA conference.
Teva has been accused of "playing games" with Mylan by acquiring a 1.35% stake in the generics firm weeks after having a $40bn (EUR36bn) takeover bid snubbed.
Following its three acquisitions over the last year, AMRI is now looking to extend its footprint into India further with the acquisition of a FDA-approved API site, William Marth, president and CEO of AMRI, told attendees at the Barclays Global Healthcare...
With operations in more than 100 countries, the world’s largest CRO Quintiles is now looking to extend its global reach even farther, CEO Tom Pike told investors at the Barclays Global Healthcare Conference on Tuesday.
2014 has seen record pharma M&A activity but top management of some of the key dealmakers – including Novartis, AstraZeneca and Shire – say size doesn’t always matter.
Life science sector consolidation is a concern for some biomanufacturers, who say mega mergers like Merck KGaA’s $17bn acquisition of Sigma-Aldrich will limit their ability to negotiate on prices.
Increased emphasis on global clinical trials is promoting consolidation of contract research organisations (CROs), according to an industry report by M&A services firm 11T Partners.
Huntingdon Life Sciences has acquired contract research and animal models firm Harlan Laboratories, making it the third largest preclinical research organisation, according to the company.
The recent rumours of mega-mergers are behind a sudden drop in the share value of contract research organisations (CROs) but should bring long-term benefits, says an analyst.
Aenova says the acquisition of Haupt Pharma and Patheon’s merger with DSM are evidence of consolidation in the CMO industry, as it looks to further increase its global footprint.
Whether McKesson will relaunch its bid to acquire German logistics firm Celsio has been questioned by analysts after the proposed $8.3bn (€6.1bn) takeover bid fell through.
Patheon is the world’s largest pharmaceutical development services (PDS) provider and third largest contract manufacturer, according to a report released yesterday.
Royal DSM wants to merge its pharmaceutical products business with Patheon and has signed a deal with the latter's owner, investment group JLL Partners.
AAIPharma and Cambridge Major labs (CML) have completed their merger with the former's CEO taking the leading position, plus news from SNBL and Aesica. Welcome to Outsourcing-Pharma's People on the Move.
AAIPharma says the merger with Cambridge Major Laboratories (CML) will bring clients the benefits of integrated Chemistry and Manufacturing Controls (CMC) services from two high-growth CMOs.
